NOVO.B.DK

270.9

+4.47%↑

GMAB.DK

1,681

+1.6%↑

HLUNB.DK

42.58

+1.62%↑

ZEAL.DK

300.5

+0.2%↑

AMBUB.DK

64.45

+4.2%↑

NOVO.B.DK

270.9

+4.47%↑

GMAB.DK

1,681

+1.6%↑

HLUNB.DK

42.58

+1.62%↑

ZEAL.DK

300.5

+0.2%↑

AMBUB.DK

64.45

+4.2%↑

NOVO.B.DK

270.9

+4.47%↑

GMAB.DK

1,681

+1.6%↑

HLUNB.DK

42.58

+1.62%↑

ZEAL.DK

300.5

+0.2%↑

AMBUB.DK

64.45

+4.2%↑

NOVO.B.DK

270.9

+4.47%↑

GMAB.DK

1,681

+1.6%↑

HLUNB.DK

42.58

+1.62%↑

ZEAL.DK

300.5

+0.2%↑

AMBUB.DK

64.45

+4.2%↑

NOVO.B.DK

270.9

+4.47%↑

GMAB.DK

1,681

+1.6%↑

HLUNB.DK

42.58

+1.62%↑

ZEAL.DK

300.5

+0.2%↑

AMBUB.DK

64.45

+4.2%↑

Search

Coloplast A-S (Class B)

Deschisă

399 1.79

Rezumat

Modificarea prețului

24h

Curent

Minim

392.4

Maxim

399.1

Indicatori cheie

By Trading Economics

Venit

522M

1.4B

Vânzări

83M

7B

P/E

Medie Sector

22.883

67.147

EPS

6.32

Randament dividend

5.69

Marjă de profit

19.835

Angajați

16,983

EBITDA

309M

2.3B

Recomandări

By TipRanks

Recomandări

Neutru

Prognoză pe 12 luni

+11.86% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

5.69%

2.36%

Următoarele câștiguri

12 mai 2026

Data viitoare de dividende

20 mai 2026

Următoarea dată ex-dividende

18 mai 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

-27B

91B

Deschiderea anterioară

397.21

Închiderea anterioară

399

Coloplast A-S (Class B) Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

30 apr. 2026, 23:08 UTC

Câștiguri

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30 apr. 2026, 23:07 UTC

Câștiguri

Australia's Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30 apr. 2026, 22:20 UTC

Câștiguri

Australia's ANZ Raises 1st Half Profit 9%, Warns of Coming Iran Impacts

30 apr. 2026, 23:48 UTC

Market Talk

Nikkei May Rise After Gains on Wall Street -- Market Talk

30 apr. 2026, 23:47 UTC

Market Talk

Global Equities Roundup: Market Talk

30 apr. 2026, 23:47 UTC

Market Talk

Coles's Earnings Views Likely to Edge Down Despite Positives -- Market Talk

30 apr. 2026, 23:27 UTC

Market Talk

Liontown Lithium Recovery Expected to Improve -- Market Talk

30 apr. 2026, 23:22 UTC

Câștiguri

Apple's Incoming CEO John Ternus Makes Appearance as Company Bests Expectations -- Update

30 apr. 2026, 23:20 UTC

Market Talk

Wildcat Resources Stands Out Among Lithium Developers -- Market Talk

30 apr. 2026, 22:52 UTC

Câștiguri

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30 apr. 2026, 22:33 UTC

Câștiguri

Zhejiang Expressway: Impairment Loss Weighed on Net >0576.HK

30 apr. 2026, 22:32 UTC

Câștiguri

Zhejiang Expressway 1Q Net CNY1.31B Vs. Net CNY1.48B >0576.HK

30 apr. 2026, 22:32 UTC

Câștiguri

Zhejiang Expressway 1Q Rev CNY5.32B Vs. CNY4.36B >0576.HK

30 apr. 2026, 22:24 UTC

Achiziții, Fuziuni, Preluări

Mineral Resources: Also Reflects Time Needed to Implement Corporate Restructure For JV

30 apr. 2026, 22:23 UTC

Achiziții, Fuziuni, Preluări

Mineral Resources: Revised Timetable Reflects Time Needed to Get Regulatory Approvals

30 apr. 2026, 22:23 UTC

Achiziții, Fuziuni, Preluări

Mineral Resources: Now Expects Deal to Complete in 1H FY2027

30 apr. 2026, 22:23 UTC

Achiziții, Fuziuni, Preluări

Mineral Resources: Executes Key Formal Agreements With Posco on Stake Sale

30 apr. 2026, 22:11 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

30 apr. 2026, 22:11 UTC

Market Talk

Global Equities Roundup: Market Talk

30 apr. 2026, 22:11 UTC

Market Talk

Apple Says Demand for Lower-Cost Laptop is Off the Charts -- Market Talk

30 apr. 2026, 22:05 UTC

Câștiguri

Australia's ANZ Raises 1H Profit 9%, Warns of Coming Iran Impacts

30 apr. 2026, 21:57 UTC

Câștiguri

ANZ CEO: Increase in Collective Provisions Reflects Risk>ANZ.AU

30 apr. 2026, 21:56 UTC

Câștiguri

ANZ CEO: Minimal Impact on ANZ's Credit, Capital, Liquidity>ANZ.AU

30 apr. 2026, 21:56 UTC

Câștiguri

ANZ CEO: No Material Increase in New Cases of Household Hardship>ANZ.AU

30 apr. 2026, 21:55 UTC

Câștiguri

ANZ CEO: Households Entered Crisis With Generally Strong Balance Sheets>ANZ.AU

30 apr. 2026, 21:54 UTC

Câștiguri

ANZ CEO: No Material Change in Overall Corporate Borrowing Behavior >ANZ.AU

30 apr. 2026, 21:54 UTC

Câștiguri

ANZ CEO: Corporate Customers Have Been Building Capital, Liquidity Against Shocks>ANZ.AU

30 apr. 2026, 21:53 UTC

Câștiguri

ANZ CEO: Much of Iran Conflict's Potential Impact Remains Ahead>ANZ.AU

30 apr. 2026, 21:49 UTC

Câștiguri

ANZ Group 1H Total Operating Income A$11.20B Vs. A$10.995B>ANZ.AU

30 apr. 2026, 21:49 UTC

Câștiguri

ANZ Group 1H Customer Deposits A$770.7B Vs. A$756.6B>ANZ.AU

Comparație

Modificare preț

Coloplast A-S (Class B) Așteptări

Obiectiv de preț

By TipRanks

11.86% sus

Prognoză pe 12 luni

Medie 901.38 DKK  11.86%

Maxim 1,056 DKK

Minim 720 DKK

În baza a 8 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruColoplast A-S (Class B) - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

8 ratings

2

Cumpărare

4

Păstrare

2

Vânzare

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Coloplast A-S (Class B)

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.
help-icon Live chat